All Industries

Top healthtech Companies

659 healthtech companies, sorted by total funding raised.

CRISPR Therapeutics AG Common SharesIPO

Gene editing company using CRISPR/Cas9 technology to develop transformative medicines for serious...

Zug, Switzerland201–500healthtech, Biotech
Corporate Round·$194.0M·Sep 2016
Twist BioscienceIPO

Synthetic biology company that uses a proprietary silicon-based platform to manufacture high-qual...

South San Francisco, United States1001–5000Biotech, healthtech
Extension Round·$193.1M·Jun 2017
Omada HealthIPO

Virtual clinic enabling health through sustainable behavior change

San Francisco, United States501–1000Artificial Intelligence, Healthcare
Series E·$192.0M·Feb 2022
Maze TherapeuticsIPO

Translating human genetics insights into a pipeline of novel precision therapies for common diseases

South San Francisco, United States51–200Healthcare, healthtech
Venture Unknown·$190.0M·Jan 2022
National Vision HoldingsIPO

One of the largest optical retail chains in the US with over 1,200 stores across 38 states and Pu...

Duluth, United States5001–10000healthtech, retail
Private Equity·$190.0M·Feb 2014
Mirum PharmaceuticalsIPO

Mirum Pharmaceuticals, Inc. is a clinical-stage therapeutics company developing a novel approach ...

Foster City, United States201–500Biotech, Therapeutics
Private Equity·$188.5M·Dec 2025
Neurogene Inc.IPO

Clinical-stage gene therapy company developing life-changing genetic medicines for rare neurologi...

New York, United States51–200healthtech, biotech
Series B·$183.5M·Dec 2020
Sionna TherapeuticsIPO

Clinical-stage biopharmaceutical company developing NBD1-stabilizing therapies for cystic fibrosi...

Waltham, United States11–50healthtech, Biotech
Series C·$182.0M·Mar 2024
Caribou BiosciencesIPO

Clinical-stage biopharmaceutical company developing genome-edited allogeneic CAR-T cell therapies...

Berkeley, United States51–200Biotech, Life Sciences
Corporate Round·$181.0M·Jul 2023
Candel TherapeuticsIPO

Clinical-stage biopharmaceutical company developing viral immunotherapies that induce immunogenic...

Needham, United States11–50healthtech, biotech
Corporate Round·$180.0M·Feb 2026
AdageneIPO

Adagene is a clinical-stage biotechnology company focused on developing innovative antibodies wit...

Suzhou, China51–200Life Sciences, Artificial Intelligence
Corporate Round·$180.0M·Jul 2025
ImmunityBioIPO

Biotech company developing next-generation immunotherapies targeting cancer and infectious diseases.

Culver City, United States201–500healthtech, Biotech
Venture Unknown·$180.0M·Dec 2025
Organigram Global Inc. Common SharesIPO

Organigram Global is Canada's largest licensed cannabis producer, developing consumer brands and ...

Moncton, Canada501–1000healthtech, Healthcare
Corporate Round·$175.8M·Mar 2021
Ironwood PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing therapies for gastrointestinal diseases ...

Boston, United States201–500Biotech, Healthcare
Corporate Round·$175.0M·Feb 2019
Black Diamond TherapeuticsIPO

Black Diamond discovers and develops next-wave precision cancer medicines to treat patients with ...

Cambridge, United States51–200Biotech, Oncology
Series C·$170.0M·Dec 2019
C4 TherapeuticsIPO

Clinical-stage biopharmaceutical company pioneering targeted protein degradation therapies for ca...

Watertown, United States51–200healthtech, biotech
Series B·$170.0M·Jun 2020
BioAge LabsIPO

Extending healthy human lifespan by developing treatments that target the molecular causes of hum...

San Francisco Bay Area, United States51–200Artificial Intelligence, Healthcare
Series D·$170.0M·Feb 2024
Apogee TherapeuticsIPO

Apogee Therapeutics is a clinical-stage biotechnology company advancing differentiated biologics ...

South San Francisco, United States51–200healthtech, Biotech
Series B·$169.0M·Dec 2022
Sutro BiopharmaIPO

Sutro Biopharma is a clinical-stage biopharmaceutical company developing next-generation cancer t...

South San Francisco, United States201–500healthtech, Biotech
Series E·$168.9M·Jul 2018
Kymera TherapeuticsIPO

Kymera Therapeutics is pioneering a transformative approach to treating previously untreatable di...

Boston, United States51–200Biotech, Healthcare
Series C·$167.0M·Mar 2020
4D Molecular TherapeuticsIPO

Clinical-stage biotherapeutics company harnessing directed evolution for targeted genetic medicines.

Emeryville, United Stateshealthtech
Series C·$165.0M·Jun 2020
Dyne TherapeuticsIPO

Biotechnology company developing nucleic acid therapies for genetically driven neuromuscular dise...

Waltham, United States201–500healthtech, Biotech
Series B·$165.0M·Aug 2020
ALTO NEUROSCIENCE, INC.

R&D company with 1 SBIR/STTR awards from Department of Health and Human Services.

LOS ALTOS, United States1–10Biotech, Healthcare
Growth Equity·$165.0M·Mar 2026
Editas MedicineIPO

Clinical-stage biotechnology company developing CRISPR-based genomic medicines for people with se...

Cambridge, United States201–500Biotech, Genomics
Series B·$163.0M·Aug 2015
AlectorIPO

Alector is a clinical-stage biopharmaceutical company focused on immunotherapy for neurodegenerat...

South San Francisco, United States51–200Biotech, Healthcare
Series E·$162.5M·Jul 2018